IMV to Provide Updated Clinical Data at 2019 ASCO Annual Meeting on Lead Candidate DPX-Survivac in Ovarian Cancer and Other Solid Tumors

On April 18, 2019 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, reported that two of its abstracts have been accepted for presentation at the upcoming 2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which takes place May 31 – June 4 in Chicago, IL (Press release, IMV, APR 18, 2019, View Source [SID1234535206]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Despite advances in other cancer treatment regimens, ovarian cancer remains a particularly difficult-to-treat disease, and one that represents one of the most underserved areas of the treatment landscape," said Frederic Ors, Chief Executive Officer at IMV. "Our presentations at ASCO (Free ASCO Whitepaper) will allow us to update this important scientific audience on the potential of DPX-Survivac monotherapy and on the progress we have made since our groundbreaking ASCO (Free ASCO Whitepaper) 2018 presentation."

Presentation details are as follows:

Poster Title: "DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE1 trial): T cell responses and tumor infiltration correlate with tumor regression."
Abstract Number: 5576
Session Title: Gynecologic Cancer
Date and Time: June 1, 2019, 1:15 – 4:15 p.m. CT

Poster Title: "Early response assessment through multiparametric MRI based endpoints in a phase II multicenter study evaluating the efficacy of DPX-Survivac, intermittent low dose cyclophosphamide (CPA) and pembrolizumab combination study in subjects with solid tumors."
Abstract Number: e14245
Session Title: online publication only on May 15, 2019, 5:00 p.m. ET

ASCO will publish the official abstracts on its meeting website in advance of the ASCO (Free ASCO Whitepaper) Annual Meeting at 5:00 p.m. ET on May 15. The cut-off date for inclusion of data in the abstract was February 12, 2019. The final conference presentation will include additional data collected between the abstract submission cutoff and the presentation itself.